Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD276-positive circulating endothelial cells as a biomarker in advanced clear cell renal cell carcinoma
NL-OMON45737Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sunitinib and pazopanib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Erasmus MC. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
sunitinibpazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON45737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45737.